STAT News

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

The Pharma Data

MARCH 16, 2021

TREMFYA is the first and only treatment approved for both adults with moderate to severe plaque PsO and for adults with active PsA that selectively inhibits IL-23, a cytokine that is a key driver of the inflammatory immune response associated with the symptoms of these chronic autoimmune diseases. TREMFYA was approved in the U.S.

Medicine 52

Medicine Doctors Doctor Development 52

The Pharma Data

APRIL 22, 2023

When the researchers switched the backbone of the Y-shaped antibody of one of the most common IgG antibodies in the blood, IgG1, to the backbone of a theoretically more potent antibody, IgG3, they saw a much stronger immune response. The studies were carried out in human cells and with mice.

Antibody 40

Antibody Immune Response Protein Research 40

Drug Discovery World

APRIL 14, 2023

Doctors said not to worry. Jaffee’s award lecture will be held on Monday April 17 at 4:45pm ET. Schreiber’s award lecture will be held on Monday April 17 at 5:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

The Pharma Data

JANUARY 4, 2021

CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumor activity by potentially amplifying the immune response. “We TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Dual blockade of the TIGIT and PD-L1 pathways.

Immune Response 52

Immune Response Medicine Protein Gene 52

The Pharma Data

JANUARY 21, 2021

Doctors need better tools to evaluate the status of COVID-19 patients as early as possible because many of the treatments—such as monoclonal antibodies—are in short supply, and we know that some patients will get better without intensive treatments,” said co-senior author Andrew E. The research was published in the journal JCI Insight.

Research 52

Research DNA Hormones Vaccination 52

pharmaphorum

NOVEMBER 23, 2020

Doctors now have another option to choose from to combat the disease, following EUAs for drugs such as Eli Lilly’s baricitinib and Gilead’s Veklury (remdesivir). Regeneron’s antibodies were designed to combat SARS-CoV-02 using the company’s proprietary genetically modified mice, which have been engineered to have a human immune system.

Antibody 52

Antibody Immune Response Trials Engineer 52

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92